Ikonisys Enhances Financial Position Through Capital Increase

Ikonisys SA, the cancer detection company, has completed a €478k capital increase via private placement. This move supports the company's consolidation, following Hospitex's integration, and enriches its shareholder base and free float. Ikonisys aims to bolster working capital and extend financial visibility using the capital raised.

The capital increase, executed without shareholder subscription rights, received board approval on September 27, 2024. Settlement of the new shares will occur on October 16, 2024. The operation did not necessitate AMF approval. A total of 312,675 new shares were issued at a 2% discount.

Post-transaction, Ikonisys considers it can meet financial needs beyond 12 months. Shareholder holding was slightly diluted, impacting share ownership proportions. The transaction ensures liquidity support and aligns with past funding efforts.